| Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis (NCT03803540) | Puerta de Hierro University Hospital | 2022-05-01 |
| A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects (NCT05294458) | AstraZeneca | 2022-03-28 |
| Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease (NCT04182646) | Asian Institute of Gastroenterology, India | 2022-02-25 |
| A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants (NCT05053165) | LISCure Biosciences | 2022-01-04 |
| The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis (NCT05065593) | Hacettepe University | 2021-09-30 |
| Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis (NCT05573204) | Tanta University | 2021-09-01 |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (NCT05016882) | Novo Nordisk A/S | 2021-08-31 |
| MLCT Oil for Fatty Liver - PASS Trial (NCT05217745) | National University Hospital, Singapore | 2021-08-05 |
| Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (NCT04669158) | Stanford University | 2021-07-30 |
| Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH (NCT04872777) | Milton S. Hershey Medical Center | 2021-06-08 |
| Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease (NCT05728697) | Brigham and Women's Hospital | 2021-06-01 |
| The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects (NCT04829123) | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | 2021-05-14 |
| A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers (NCT04931147) | Redx Pharma Ltd | 2021-05-13 |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (NCT04822181) | Novo Nordisk A/S | 2021-04-01 |
| Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study (NCT04800094) | Philips Clinical & Medical Affairs Global | 2021-03-02 |
| A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men (NCT04722653) | Novo Nordisk A/S | 2021-02-02 |
| Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis (NCT03962608) | Yaqrit Ltd | 2021-01-31 |
| "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases". (NCT04690972) | Institut National de la Santé Et de la Recherche Médicale, France | 2021-01-14 |
| Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD. (NCT04579874) | Fibronostics USA, Inc | 2021-01-07 |
| Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study (NCT04657523) | Philips Clinical & Medical Affairs Global | 2020-10-30 |
| Integrated Diagnostics for Early Diagnosis of Liver Disease (NCT04666402) | Manchester University NHS Foundation Trust | 2020-10-21 |
| The Olmsted NAFLD Epidemiology Study (TONES) (NCT04365855) | Mayo Clinic | 2020-10-10 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis (NCT04171765) | Genentech, Inc. | 2020-09-30 |
| Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males (NCT06308861) | J2H Biotech | 2020-08-12 |
| The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects (NCT04422496) | Sunshine Lake Pharma Co., Ltd. | 2020-08-10 |
| Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease (NCT06176079) | Michael Ohliger, MD PhD | 2020-07-22 |
| The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral (NCT07580482) | University of Kansas Medical Center | 2020-07-15 |
| To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes (NCT03950505) | Yonsei University | 2020-05-29 |
| A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH (NCT04378010) | Enanta Pharmaceuticals, Inc | 2020-01-27 |
| Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) (NCT04198805) | Naga P. Chalasani | 2020-01-03 |
| NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal (NCT03864835) | Milton S. Hershey Medical Center | 2019-11-01 |
| A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (NCT04142424) | AstraZeneca | 2019-10-28 |
| Glucagon Resistance in Patients With NAFLD (NCT04042142) | University of Aarhus | 2019-10-05 |
| Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH) (NCT04537780) | Tanta University | 2019-08-20 |
| Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) (NCT03884075) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2019-07-24 |
| A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus (NCT03969719) | Pfizer | 2019-07-18 |
| Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) (NCT03883607) | Genfit | 2019-06-25 |
| A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage (NCT03987451) | Novo Nordisk A/S | 2019-06-18 |
| Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis (NCT03863574) | Zydus Therapeutics Inc. | 2019-06-12 |
| Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis (NCT05357352) | Methodist Health System | 2019-05-24 |
| Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease (NCT03437720) | Sanofi | 2019-05-23 |
| Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery (NCT04501042) | National Taiwan University Hospital | 2019-05-16 |
| Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease (NCT03839082) | University of Michigan | 2019-03-20 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) (NCT03812029) | Enyo Pharma | 2019-01-30 |
| Bariatric Surgery Versus Non-alcoholic Steato-hepatitis (NCT03524365) | Catholic University of the Sacred Heart | 2018-12-06 |
| An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis (NCT03656068) | Pinnacle Clinical Research, PLLC | 2018-12-04 |
| Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization (NCT04571957) | Institute of Liver and Biliary Sciences, India | 2018-12-01 |
| Prognostic Significance of Fatty Liver Disease in Bariatric Patients (NCT03535142) | Esbjerg Hospital - University Hospital of Southern Denmark | 2018-08-15 |
| Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis (NCT03664596) | Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan | 2018-08-01 |
| Technical Validation of MR Biomarkers of Obesity-Associated NAFLD (NCT03674528) | University of Wisconsin, Madison | 2018-05-04 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NCT03421431) | Enanta Pharmaceuticals, Inc | 2018-04-25 |
| The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study (NCT03734510) | National Nutrition and Food Technology Institute | 2018-03-01 |
| Coffee Consumption and NASH in the French Population. (NCT03432377) | Versailles Hospital | 2017-11-15 |
| European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD) (NCT04190849) | Cambridge University Hospitals NHS Foundation Trust | 2017-11-14 |
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis (NCT03198572) | Fudan University | 2017-08-16 |
| The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease (NCT03377140) | National Nutrition and Food Technology Institute | 2017-06-01 |
| The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease (NCT03377153) | National Nutrition and Food Technology Institute | 2017-06-01 |
| EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity (NCT02880189) | Mayo Clinic | 2016-12-01 |
| Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. (NCT02970942) | Novo Nordisk A/S | 2016-11-30 |
| Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) (NCT02787304) | Mirum Pharmaceuticals, Inc. | 2016-10-24 |
| Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) (NCT02912260) | Madrigal Pharmaceuticals, Inc. | 2016-10-18 |
| A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (NCT02784444) | Cirius Therapeutics, Inc. | 2016-09-14 |
| Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI (NCT03198104) | Perspectum | 2016-04-01 |
| Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects (NCT02681055) | MediciNova | 2016-03-01 |
| Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis. (NCT02721264) | Institute of Liver and Biliary Sciences, India | 2016-03-01 |
| Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (NCT02686762) | Conatus Pharmaceuticals Inc. | 2016-01-26 |
| Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis (NCT01617772) | Tehran University of Medical Sciences | 2016-01-01 |
| The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis (NCT02528305) | University of Bath | 2015-10-01 |
| The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults (NCT03142867) | The Geneva Foundation | 2015-08-25 |
| Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis (NCT02541045) | Hospital General de Mexico | 2015-08-01 |
| A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) (NCT02413372) | Bristol-Myers Squibb | 2015-05-08 |
| A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) (NCT03400163) | Bristol-Myers Squibb | 2015-05-08 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (NCT02279524) | Galmed Research and Development, Ltd. | 2015-04-29 |
| BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH (NCT02314026) | Meridian Bioscience, Inc. | 2015-03-01 |
| Safety and Tolerability Study of SHP626 in Overweight and Obese Adults (NCT02287779) | Mirum Pharmaceuticals, Inc. | 2015-01-19 |
| The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver (NCT02530138) | National Nutrition and Food Technology Institute | 2014-08-01 |
| The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (NCT02395900) | National Nutrition and Food Technology Institute | 2014-03-01 |
| The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis (NCT02231333) | Institute of Liver and Biliary Sciences, India | 2013-07-01 |
| Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD (NCT02075164) | Prof. Michael Trauner, MD | 2013-05-01 |
| Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis (NCT01766713) | University of California, San Diego | 2013-01-01 |
| Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients (NCT01695083) | Assistance Publique - Hôpitaux de Paris | 2012-10-01 |
| The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis (NCT01791959) | National Nutrition and Food Technology Institute | 2012-03-01 |
| Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study. (NCT01696487) | Medical University of Vienna | 2012-02-01 |
| Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial (NCT01279434) | Institute of Liver and Biliary Sciences, India | 2012-01-01 |
| Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis (NCT01384578) | Institute of Liver and Biliary Sciences, India | 2011-07-01 |
| Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls (NCT01674972) | University Hospital, Basel, Switzerland | 2011-01-01 |
| The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NCT01278056) | Crolll Gmbh | 2010-03-01 |
| Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH) (NCT01056133) | Johane Allard | 2009-10-01 |
| The Effect of Protandim on Non-alcoholic Steatohepatitis (NCT00977730) | University of Colorado, Denver | 2008-07-01 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (NCT00678587) | GlaxoSmithKline | 2008-06-01 |
| Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children (NCT00677183) | Medical College of Wisconsin | 2008-05-01 |
| Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis (NCT00680407) | Madaus Inc | 2008-04-01 |
| A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831 (NCT00668070) | Astellas Pharma Inc | 2008-04-01 |
| Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) (NCT00681408) | University of Virginia | 2007-03-01 |
| Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) (NCT01761370) | National University Hospital, Singapore | 2005-11-01 |
| A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis (NCT00492700) | Association pour la Recherche sur les Maladies Hépatiques Virales | 2003-01-01 |